Janus Henderson Group
BCAX

Janus Henderson Group’s Bicara Therapeutics BCAX Stock Holding History

Janus Henderson Group’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$66.4M Buy
3,339,218
+692,933
+26% +$11.9M 0.03% 354
2025
Q4 		$44.5M Buy
+2,646,285
New +$45.2M 0.02% 438
2025
Q2 		– Sell
-1,343,754
Closed -$18M – 2519
2025
Q1 		$18M Buy
1,343,754
+479,908
+56% +$6.37M 0.01% 590
2024
Q4 		$15M Sell
863,846
-324,345
-27% -$6.75M 0.01% 648
2024
Q3 		$30.3M Buy
+1,188,191
New +$30.3M 0.02% 492

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $173M AUM

Janus Henderson Group's BCAX Position: Q1 2026 in Review

Janus Henderson Group increased its Bicara Therapeutics (BCAX) stake by 26% in Q1 2026, buying an estimated $11.9M and bringing the position to 3,339,218 shares worth $66.4M. The position accounts for 0.03% of the portfolio, ranked #354.

Janus Henderson Group first reported a position in BCAX in Q3 2024 and has held it in 5 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Janus Henderson Group held 3,339,218 shares of Bicara Therapeutics worth $66.4M as of Q1 2026.
  • Janus Henderson Group bought 692,933 Bicara Therapeutics shares in Q1 2026, an estimated $11.9M.
  • Bicara Therapeutics made up 0.03% of Janus Henderson Group's portfolio in Q1 2026, its #354 holding.
  • Janus Henderson Group first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.